The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / August / From Training Burden to Training Value 
Business & Regulation Development & Clinical Regulation & Standards Business & Trends Technology & Manufacturing Sponsored

From Training Burden to Training Value 

Why effective study training depends on relevance, timing, and oversight.

08/14/2026 0 min read Interview

Share

Study training is essential to clinical trial compliance, but assigning, tracking, and documenting it across global studies can consume time better spent improving training quality and impact. Reducing that burden helps ensure that each person receives the right training at the right time.

Tine De Pla of Amgen and Aidan Gannon of Veeva Systems discuss how role-based automation can strengthen oversight, reduce unnecessary training, and deliver more timely, useful learning. They also explore the links between effective training, patient safety, trial execution, and data quality.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Ali Tavassoli
Small Molecules Drug Discovery Development & Clinical
Musings from The Power List: Ali Tavassoli

September 10, 2026

8 min read

Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology

Musings from The Power List: Miguel Forte
Cell & Gene Drug Discovery Development & Clinical
Musings from The Power List: Miguel Forte

September 8, 2026

4 min read

Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy

Musings from The Power List Peng Lu
Small Molecules Development & Clinical Small Molecules
Musings from The Power List: Peng Lu

September 4, 2026

2 min read

Peng Lu argues that small molecules remain indispensable as AI transforms drug development

What Will Drug Development Look Like in 2036?
Future of Pharma Future of Pharma Business & Trends
What Will Drug Development Look Like in 2036?

September 3, 2026

7 min read

Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: